Viking Therapeutics (VKTX) Investor Presentation - Slideshow

VK2809 for NASH (Metabolic Disease Program) - VK2809 is a novel, selective thyroid receptor-β (TRβ) agonist being developed for NASH [8, 97] - Phase 2a results showed VK2809 significantly reduced liver fat content and lipids [8, 97] - In a diet-induced NASH model, VK2809 treatment resulted in a 70% reduction in triglycerides, a 64.6% reduction in cholesterol, and a 79.5% reduction in total lipids, all with p < 0.0001 [22] - The same model showed a 39.7% reduction in NAS with p < 0.0001 [22] - In a Phase 1b study, VK2809 demonstrated placebo-adjusted LDL reductions of 15.2% (p=0.026) at 5.0 mg, 27.1% at 10.0 mg (p=0.0003), 41.2% at 20.0 mg (p<0.0001), and 36.6% at 40.0 mg (p<0.0001) [34] - The same study showed placebo-adjusted triglyceride reductions of 34.8% (p=0.052) at 5.0 mg, 61.0% at 10.0 mg (p=0.0019), 62.1% at 20.0 mg (p=0.0007), and 78.6% at 40.0 mg (p=0.0001) [34] - In a Phase 2a trial, VK2809 cohorts experienced relative reductions in liver fat, with the 5 mg QD cohort showing a 78% reduction, the 10 mg QOD cohort showing a 72% reduction, and the 10 mg QD cohort showing a 76% reduction [45] - In the same Phase 2a trial, 87.9% of combined VK2809 cohorts experienced at least a 30% reduction in liver fat content [47] VK0214 for X-ALD (Rare Disease Program) - VK0214 is a novel, selective thyroid receptor-β (TRβ) agonist being developed for X-ALD [8, 97] - In vivo data showed VK0214 improved key biomarkers [8, 97] - In an ABCD1 knockout mouse model, VK0214 treatment resulted in reductions in plasma VLCFA-LPC, including a 29% reduction in C26:0, a 21% reduction in C24:0, a 43% reduction in C22:0, and a 54% reduction in C20:0 after 6 weeks (all p < 0.0001) [87]